Reckitt Continues Asian Push With $724M Paras Purchase
This article was originally published in The Tan Sheet
Executive Summary
Reckitt Benckiser continues expanding its Asian business with the purchase of Paras Pharmaceuticals Ltd., a top OTC manufacturer in India, where nonprescription drug sales are growing 23% annually.
You may also be interested in...
Emerging Markets Compound Stagnation In Developed Economies
The rapid growth of emerging markets – key regions for many OTC firms – is a major contributor to the industrialized world’s economic stagnation, an HSBC analyst says. Emerging market growth hinders recovery in developed markets by driving up commodity and oil costs, breaking the link in the traditional boom-bust economic cycle.
Emerging Markets Compound Stagnation In Developed Economies
The rapid growth of emerging markets – key regions for many OTC firms – is a major contributor to the industrialized world’s economic stagnation, an HSBC analyst says. Emerging market growth hinders recovery in developed markets by driving up commodity and oil costs, breaking the link in the traditional boom-bust economic cycle.
Reckitt Reorganizes To Develop Health Care, Emerging Markets
Reckitt Benckiser reorganizes to emphasize consumer healthcare and emerging markets, both high growth areas for the firm. The firm’s fiscal 2011 total net revenues were $15 billion, driven by emerging markets and brands including Mucinex decongestants, Nurofen analgesics and Strepsils sore throat treatments.